Table 1.
IC50s (μg/L) of anticancer drugs for different osteosarcoma cells
| ADM | VCR | MTX | CDDP | As2O3 | |
|---|---|---|---|---|---|
| Saos-2 | 126.31 ± 21.67 | 7.45 ± 1.29 | 24.24 ± 4.58 | 121.46 ± 17.34 | 869.25 ± 196.45 |
| Saos-2-Ad-null | 131.58 ± 19.19 | 6.98 ± 1.36 | 25.65 ± 3.98 | 98.83 ± 15.98 | 850.39 ± 162.98 |
| Saos-2-Ad-PDCD5 | 85.74 ± 17.45a | 5.63 ± 0.95a | 16.27 ± 2.73a | 67.56 ± 12.72a | 571.18 ± 10.65a |
| Saos-2/ADM | 6946.47 ± 1189.58 | 373.96 ± 27.67 | 42.45 ± 13.01 | 176.17 ± 37.73 | 1128.42 ± 276.68 |
| Saos-2/ADM-Ad-null | 6754.76 ± 957.37 | 384.93 ± 41.84 | 41.28 ± 10.47 | 186.12 ± 12.98 | 1098.34 ± 194.34 |
| Saos-2/ADM-Ad-PDCD5 | 4638.14 ± 914.69b | 218.45 ± 46.87b | 26.22 ± 3.97b | 127.76 ± 14.61b | 673.98 ± 15.66b |
Note: survival rate of osteosarcoma cell to anticancer agents were evaluated by MTT assay as described in materials and methods. The IC50 values were determined by the dose-effect curves of different anticancer agents. Data are means ± SD of different independent experiment.
a
P < 0.05, compared with Saos-2-Ad-null;
b
P < 0.05, compared with Saos-2/ADM-Ad-null.